RA CAPITAL MANAGEMENT, L.P.
10% Owner; Director; Director, 10% Owner · 59 filings · Latest: Aug 12, 2026
Acrivon Therapeutics, Inc.
Acumen Pharmaceuticals, Inc.
Adicet Bio, Inc.
ARS Pharmaceuticals, Inc.
Artiva Biotherapeutics, Inc.
Bicara Therapeutics Inc.
Climb Bio, Inc.
Evommune, Inc.
Freenome, Inc.
Hemab Therapeutics Holdings, Inc.
Inhibikase Therapeutics, Inc.
Janux Therapeutics, Inc.
LENZ Therapeutics, Inc.
Mineralys Therapeutics, Inc.
Nkarta, Inc.
Parabilis Medicines, Inc.
PepGen Inc.
Prelude Therapeutics Inc
Septerna, Inc.
Sionna Therapeutics, Inc.
SpyGlass Pharma, Inc.
Tyra Biosciences, Inc.
Vor Biopharma Inc.
Wave Life Sciences Ltd.
Werewolf Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
VOR | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Apr 2, 2026 | Sale | $18.23 | 260,000 | $4.7M | 5,144,998 | |
MLYS | RA CAPITAL MANAGEMENT, L.P. | Director | Mar 30, 2026 | Purchase | $24.16 | 58,300 | $1.4M | 5,825,521 | |
MLYS | RA CAPITAL MANAGEMENT, L.P. | Director | Mar 27, 2026 | Purchase | $23.67 | 310,700 | $7.4M | 5,767,221 | |
WVE | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 30, 2026 | Purchase | $6.50 | 971,091 | $6.3M | 26,975,505 | |
WVE | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 27, 2026 | Purchase | $6.43 | 2,495,623 | $16.0M | 26,004,414 | |
WVE | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Mar 26, 2026 | Purchase | $6.08 | 5,305,782 | $32.3M | 23,508,791 | |
BCAX | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Feb 26, 2026 | Purchase | $16.00 | 300,000 | $4.8M | 4,603,418 | |
SGP | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Feb 9, 2026 | Purchase | $16.00 | 3,690,000 | $59.0M | 2,054,678 |
← Previous
Page 4 of 4